The first studies in the field of osteoarticular metabolism date back to the end of the 1970s, a sector in which Abiogen Pharma achieved exceptional goals with the discovery of original molecules in the class of bisphosphonates (Etidronate, Clodronate, Alendronate and Neridronate).
Neridronate is an amino-bisphosphosphonate used in metabolic osteopathies. It represents the first drug to have ever obtained an indication from the Italian authorities for a “rare disease” such as osteogenesis imperfecta and algodystrophy. Clinical studies are currently being completed to support this drug in new therapeutic indications.
In the osteoarticular field, studies are also underway for new products with a strong chondroprotective action, to be used in osteoarthritis. Specifically, various intra-articular formulations of hyaluronic acid associated with other clodronate and collagen compounds are in advanced clinical stage in order to offer the doctor more options depending on the type of patient.
Clinical developments of compounds dedicated to supporting muscle trophism have recently been completed.